Teper, S.; Ledwoń, D.; Romaniszyn-Kania, P.; Sendecki, A.; Tuszy, A.; Nycz, J.; Mitas, A.W.; Figurska, M.; Wylęgała, E.; Rękas, M.
Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study. J. Clin. Med. 2025, 14, 6771.
https://doi.org/10.3390/jcm14196771
AMA Style
Teper S, Ledwoń D, Romaniszyn-Kania P, Sendecki A, Tuszy A, Nycz J, Mitas AW, Figurska M, Wylęgała E, Rękas M.
Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study. Journal of Clinical Medicine. 2025; 14(19):6771.
https://doi.org/10.3390/jcm14196771
Chicago/Turabian Style
Teper, Sławomir, Daniel Ledwoń, Patrycja Romaniszyn-Kania, Adam Sendecki, Aleksandra Tuszy, Julia Nycz, Andrzej W. Mitas, Małgorzata Figurska, Edward Wylęgała, and Marek Rękas.
2025. "Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study" Journal of Clinical Medicine 14, no. 19: 6771.
https://doi.org/10.3390/jcm14196771
APA Style
Teper, S., Ledwoń, D., Romaniszyn-Kania, P., Sendecki, A., Tuszy, A., Nycz, J., Mitas, A. W., Figurska, M., Wylęgała, E., & Rękas, M.
(2025). Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study. Journal of Clinical Medicine, 14(19), 6771.
https://doi.org/10.3390/jcm14196771
